Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.
antiviral
prophylactic
respiratory syncytial virus (RSV)
therapeutic
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 04 2022
27 04 2022
Historique:
received:
30
03
2022
revised:
22
04
2022
accepted:
25
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
RNA viruses like SARS-CoV-2, influenza virus, and respiratory syncytial virus (RSV) are dependent on host genes for replication. We investigated if probenecid, an FDA-approved and safe urate-lowering drug that inhibits organic anion transporters (OATs) has prophylactic or therapeutic efficacy to inhibit RSV replication in three epithelial cell lines used in RSV studies, i.e., Vero E6 cells, HEp-2 cells, and in primary normal human bronchoepithelial (NHBE) cells, and in BALB/c mice. The studies showed that nanomolar concentrations of all probenecid regimens prevent RSV strain A and B replication in vitro and RSV strain A in vivo, representing a potential prophylactic and chemotherapeutic for RSV.
Identifiants
pubmed: 35632652
pii: v14050912
doi: 10.3390/v14050912
pmc: PMC9147281
pii:
doi:
Substances chimiques
Probenecid
PO572Z7917
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Am J Physiol. 1999 Jan;276(1):F122-8
pubmed: 9887087
J Gen Virol. 1985 Oct;66 ( Pt 10):2111-24
pubmed: 2413163
J Virol. 2009 Oct;83(20):10710-8
pubmed: 19656891
Curr Med Res Opin. 2010 Sep;26(9):2175-81
pubmed: 20666690
Expert Opin Investig Drugs. 2020 Mar;29(3):285-294
pubmed: 32096420
CMAJ Open. 2021 Oct 19;9(4):E948-E956
pubmed: 34667075
Virol J. 2006 Aug 31;3:63
pubmed: 16945126
J Virol. 2002 Jul;76(14):6873-81
pubmed: 12072488
Viruses. 2019 Aug 11;11(8):
pubmed: 31405261
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
Curr Top Microbiol Immunol. 2015;386:459-77
pubmed: 25007848
J Virol. 2003 Sep;77(18):9831-44
pubmed: 12941892
J Pharm Sci. 2021 May;110(5):2274-2284
pubmed: 33607188
Sci Rep. 2017 Jul 10;7(1):4939
pubmed: 28694431
Am J Physiol Renal Physiol. 2006 Apr;290(4):F905-12
pubmed: 16291576
Clinicoecon Outcomes Res. 2014 Apr 25;6:217-25
pubmed: 24812523
Expert Opin Biol Ther. 2020 Sep;20(9):1073-1082
pubmed: 32264720
Physiol Rev. 2015 Jan;95(1):83-123
pubmed: 25540139
Sci Rep. 2021 Sep 10;11(1):18085
pubmed: 34508172
Sci Transl Med. 2020 Mar 18;12(535):
pubmed: 32188721
J Virol. 2002 Jun;76(11):5654-66
pubmed: 11991994
FASEB J. 2012 Apr;26(4):1372-86
pubmed: 22247330
Antiviral Res. 2018 Jun;154:149-157
pubmed: 29678551
Front Microbiol. 2019 May 03;10:873
pubmed: 31130923
Medicina (Kaunas). 2021 Jan 10;57(1):
pubmed: 33435164
Am J Physiol Cell Physiol. 2008 Sep;295(3):C761-7
pubmed: 18596212
Int J Mol Sci. 2020 Dec 01;21(23):
pubmed: 33271927
Am J Respir Cell Mol Biol. 2009 May;40(5):588-600
pubmed: 18952569
Open Forum Infect Dis. 2018 Feb 07;5(3):ofy031
pubmed: 29516023
Assay Drug Dev Technol. 2015 Dec;13(10):638-49
pubmed: 26192013
Annu Rev Biochem. 2010;79:37-64
pubmed: 20367032
Viruses. 2021 Dec 10;13(12):
pubmed: 34960746
J Virol. 2021 Apr 12;95(9):
pubmed: 33536179
Clin Infect Dis. 2019 May 2;68(10):1641-1649
pubmed: 30202920
Pharmaceuticals (Basel). 2013 Jan 28;6(2):124-60
pubmed: 24275945
Antimicrob Agents Chemother. 2013 Jan;57(1):475-83
pubmed: 23129053
PLoS One. 2014 Nov 21;9(11):e113100
pubmed: 25415360
Clin Microbiol Rev. 2000 Jan;13(1):1-15, table of contents
pubmed: 10627488
Curr Top Microbiol Immunol. 2013;372:193-209
pubmed: 24362691
Front Immunol. 2020 Jul 17;11:1507
pubmed: 32765520
Int J Mol Med. 2016 Jan;37(1):3-10
pubmed: 26572802
J Pediatr. 2019 Nov;214:121-127.e1
pubmed: 31378522
Nat Rev Microbiol. 2011 Dec 19;10(2):137-49
pubmed: 22183253